Current concepts in the pathophysiology and management of hepatic encephalopathy

Gastroenterology and Hepatology

Volumn 7, Issue 4, 2011, Pages 222-233

  Frederick, R Todd ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Ammonia; Cerebral edema; Glutaminase; Hepatic encephalopathy; Urea cycle

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 PHENYLBUTYRIC ACID; ACARBOSE; ACETYLCHOLINESTERASE; AMMONIA; AST 120; BENZOIC ACID PLUS PHENYLACETIC ACID; CARNITINE; GLUTAMATE SYNTHASE; GLUTAMINASE; HPN 100; INDOLE; INOSITOL; LACTULOSE; LIVER PROTECTIVE AGENT; METRONIDAZOLE; NEOMYCIN; OCR 002; OCTOPAMINE; ORNITHINE ASPARTATE; ORNITHINE PHENYLACETATE; PAROMOMYCIN; PREBIOTIC AGENT; RIFAXIMIN; RIVASTIGMINE; SHORT CHAIN FATTY ACID; SODIUM; THIOL; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ACID BASE BALANCE; ACUTE LIVER FAILURE; ALBUMIN DIALYSIS; ALKALOSIS; ALZHEIMER DISEASE; AMMONIA BLOOD LEVEL; AMMONIA FORMATION; ASTROCYTE; ASTROCYTOSIS; BIFIDOBACTERIACEAE; BLOOD BRAIN BARRIER; BRAIN EDEMA; CATABOLISM; COLON FLORA; CONSTIPATION; DEHYDRATION; DETOXIFICATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG USE; ELECTROLYTE INTAKE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME METABOLISM; FECES MICROFLORA; FERMENTATION; FLUID RESUSCITATION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; HYPONATREMIA; INFECTION; INFECTION RISK; INFLAMMATION; INTESTINE CELL; INTESTINE FUNCTION; INTRACELLULAR SIGNALING; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; KIDNEY FUNCTION; LACTOBACILLUS; LIVER CELL; LIVER CIRRHOSIS; META ANALYSIS (TOPIC); MITOCHONDRION; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PROMOTER REGION; PROTON TRANSPORT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SKELETAL MUSCLE; SODIUM BLOOD LEVEL; SODIUM LOAD; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; UREMIA;

EID: 79955753653     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721.
2. Bajaj JS Current and future diagnosis of hepatic encephalopathy. Metab Brain Dis. 2010;25:107-110.
3. Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138. 2332-2340.
4. Román E, Córdoba J, Torrens M, et al. Minimal hepatic encephalopathy is associated with falls Am J Gastroenterol. 2011;106:476-482.
5. Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011;140:478-487.
6. Bajaj JS, Saeian K, Schubert CM, et al Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009;50:1175-1183.
7. Groeneweg M, Quero JC, De Bruijn I, et al Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998,28:45-49.
8. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1):3-9.
9. Manning RT, Delp M. Management of hepatocerebral intoxication. N Engl J Med. 1958;258:55-62.
10. Phear EA, Sherlock S, Summerskill WH. Blood-ammonium levels in liver disease and hepatic coma Lancet. 1955;268:836-840.
11. Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol. 1987;6:1-12.
12. Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol. 1980;13:177-191.
13. Floch MH, Katz J, Conn HO. Qualitative and quantitative relationships of the fecal flora in cirrhotic patients with portal systemic encephalopathy and following portacaval anastomosis. Gastroenterology. 1970;59:70-75.
14. Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon. Effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med 1970,283:159-164.
15. LeVeen HH, LeVeen EG, LeVeen RF. Awakenings to the pathogenicity of urease and the requirement for continuous long term therapy. Biomed Pharmacother 1994;48:157-166.
16. Weber FL Jr, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979;77:235-240.
17. Nance FC, Batson RC, Kline DG. Ammonia production in germ-free Eck fistula dogs. Surgery. 1971;70:169-174.
18. Plauth M, Roske AE, Romaniuk P, Roth E, Ziebig R, Lochs H. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut. 2000,46:849-855.
19. Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology. 2002;36.1163-1171.
20. Hawkins RA, Jessy J, Mans AM, Chedid A, DeJoseph MR. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol. 1994;368:125-134.
21. Romero-Gómez M. Ramos-Guerrero R, Grande L, et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol. 2004;41:49-54.
22. Romero-Gómez M, Jover M, Del Campo JA, et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med. 2010;153:281-288
23. Romero-Gomez M, Jover M, Diaz-Gomez D, et al Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis. World J Gastroenterol. 2006;12:2406-2411
24. Haussinger D, Sies H, Gerok W. Functional hepatocyte heterogeneity in ammonia metabolism. The intercellular glutamine cycle. J Hepatol. 1985,1.3-14.
25. Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005,42:1158-1165
26. Vinay P, Lemieux G, Gougoux A, Halperin M. Regulation of glutamine metabolism in dog kidney in vivo Kidney Int. 1986;29:68-79.
27. Tizianello A, Deferrari G, Garibotto G, Robaudo C, Acquarone N, Ghiggeri GM. Renal ammoniagenesis in an early stage of metabolic acidosis in man. J Clin Invest. 1982;69:240-250.
28. Tizianello A, Deferrari G, Garibotto G, Robaudo C, Bruzzone M, Passerone GC. Renal ammoniagenesis during the adaptation to metabolic acidosis in man. Contrib Nephrol. 1982;31:40-46.
29. Tizianello A, Deferrari G, Garibotto G, et al Renal ammomagenesis in man with acute metabolic alkalosis. Contrib Nephrol. 1988;63:105-113
30. Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol. 2003,38:441-446.
31. Kramer L, Tribl B, Gendo A, et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000;31:30-34.
32. Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut. 2003;52:1041-1045.
33. Dejong CH, Deutz NE, Soeters PB. Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. J Clin Invest. 1993;92:2834-2840.
34. Tyor MP, Owen EE, Berry JN, Flanagan JF. The relative role of extremity, liver, and kidney as ammonia receivers and donors in patients with liver disease Gastroenterology. 1960;39:420-424.
35. Owen EE, Johnson JH, Tyoi MP. The effect of induced hyperammonemia on renal ammonia metabolism. J Clin Invest. 1961;40:215-221.
36. Olde Damink SW, Jalan R, Deutz NE, et al The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology. 2003,37:1277-1285. (Pubitemid 36667306)
37. Haussinger D. Low gtade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2006;43:1187-1190. (Pubitemid 43980095)
38. Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease, a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol. 2000;32:1035-1038.
39. Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF. Cerebral oedema and increased intracranial pressure in chronic liver disease Lancet. 1998;351:719-721.
40. Kavitt RT, Yang VL, Jensen DM. Cerebral edema and hyperammonemia after transjugular intrahepatic portosystemic shunt placement in a cirrhotic patient. Clin Gastroenterol Hepatol. 2008;6:1054-1056.
41. Norenberg MD, Rama Rao KV, Jayakumar AR. Signaling factors in the mechanism of ammonia neurotoxicity. Metab Brain Dis 2009;24-103-117
42. Norenberg MD, Itzhak Y, Bender AS The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv Exp Med Biol. 1997;420: 95-111
43. Mullen KD, Szauter KM, Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet. 1990;336:81-83.
44. Ahboucha S, Layrargues GP, Mamer O, Butterworth RF. Increased brain concentrations of a neuroinhibitory steroid in human hepatic encephalopathy. Ann Neurol 2005;58:169-170 (Pubitemid 40962477)
45. Baraldi M, Avallone R, Corsi L, Venturini I, Baraldi C, Zeneroli ML. Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy. Metab Brain Dis. 2009;24:81-93.
46. Ahboucha S, Butterworth RF. Role of endogenous benzodiazepine ligands and their GABA-A-associated receptors in hepatic encephalopathy Metab Brain Dis. 2005;20:425-437.
47. Avallone R, Zeneroli ML, Venturini I, et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. Gut. 1998;42:861-867. (Pubitemid 28277230)
48. Olasmaa M, Rothstein JD, Guidotti A, et al. Endogenous benzodiazepine teceptor ligands in human and animal hepatic encephalopathy. J Neurochem 1990;55:2015-2023. (Pubitemid 120021834)
49. Riggio O, Mannaioni G, Ridola L, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol 2010;105:1374-1381.
50. McClain CJ, Zieve L, Doizaki WM, Gilberstadt S, Onstad GR. Blood methanethiol in alcoholic liver disease with and without hepatic encephalopathy. Gut. 1980;21:318-323. (Pubitemid 10056065)
51. Zieve FJ, Zieve L, Doizaki WM, Gilsdorf RB. Synergism between ammonia and fatty acids in the production of coma: implications for hepatic coma. J Pharmacol Exp Ther. 1974;191:10-16.
52. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure Lancet. 1971;2:75-80.
53. Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology. 1999,117:640-644 (Pubitemid 29409250)
54. Baraldi M, Zeneroli ZL Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid Science 1982;216:427-429
55. García-Ayllón MS, Cauli O, Silveyra MX, et al. Brain cholinergic impairment in liver failure. Brain. 2008;131:2946-2956.
56. Méndez M, Méndez-López M, López L, Aller MA, Arias J, Arias JL. Acetylcholinesterase activity in an experimental rat model of Type C hepatic encephalopathy. Acta Histochem. 2011;113:358-362
57. Zarros A, Theocharis S, Skandali N, Tsakiris S. Effects of fulminant hepatic encephalopathy on the adult rat brain antioxidant status and the activities of acetylcholinesterase, (Na(+),K (+))- and Mg (2+)-ATPase: comparison of the enzymes' response to in vitro treatment with ammonia Metab Brain Dis. 2008;23:255-264.
58. Rao VL, Therrien G, Butterworth RF Choline acetyltransferase and acetylcholinesterase activities are unchanged in brain in human and experimental portal- systemic encephalopathy. Metab Brain Dis. 1994;9:401-407.
59. Basu P, Shah NJ, Krishnaswamy N, et al Transdermal rivastigmine for treatment of encephalopathy in liver cirrhosis - a randomized placebo controlled trial (TREC TRIAL) J Hepatology 2010;52(supp 1):S67-S68.
60. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104:1382-1389.
61. Angeli P, Wong F, Watson H, Ginès P; CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535-1542. (Pubitemid 44953659)
62. Vaquero J, Chung C, Blei AT. Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Ann Hepatol. 2003;2:12-22
63. Blei AT. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol. 2004;40:327-330 (Pubitemid 38115840)
64. Pedersen HR, Ring-Larsen H, Olsen NV, Larsen FS. Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetised with pentobarbital. J Hepatol 2007;47:245-252. (Pubitemid 47021255)
65. Guarner-Argente C, Sánchez E, Vidal S, et al Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients. Aliment Pharmacol Ther 2010;31:1192-1199
66. Blei AT, Cordoba J. Hepatic Encephalopathy Am J Gastroenterol. 2001, 96:1968-1976
67. Strauss E, da Costa MF. The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology. 1998;45:900-904. (Pubitemid 28321078)
68. Mumtaz K, Ahmed US, Abid S, Baig N, Hamid S, Jafri W. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. J Coll Physicians Surg Pak. 2010;20:514-518
69. Devrajani BR, Shah SZ, Devrajani T, Kumar D. Precipitating factors of hepatic encephalopathy at a tertiary care hospital Jamshoro, Hyderabad. J Pak Med Assoc. 2009;59:683-686.
70. Strauss E, Gomes de Sa Ribeiro Mde F. Bacterial infections associated with hepatic encephalopathy: prevalence and outcome Ann Hepatol. 2003;2:41-45.
71. Zushi S, Imai Y, Fukuda K, et al, Endoscopic coagulation therapy is successful for improving encephalopathy in cirrhotic patients with gastric antral vascular ectasia. Digestive Endoscopy. 2005;17:32-35. (Pubitemid 40313077)
72. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond). 2004;106:467-474. (Pubitemid 38639550)
73. Ong JP, Aggarwal A, Krieger D, et al Correlation between ammonia levels and the severity of hepatic encephalopathy Am J Med. 2003;114:188-193.
74. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration Hepatology. 1999;29:648-653.
75. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy, systematic review of randomised trials BMJ. 2004;328:1046
76. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2010 Dec 6. Epub ahead of print
77. Sharma BC, Sharma P, Agrawal A, Sarin SK Secondary prophylaxis of hepatic encephalopathy an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-891
78. Pockros P, Hassanein T, Vierling J, et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs lactulose in the treatment of low-grade hepatic encephalopathy. J Hepatology. 2009;50(supp 1):S43-S44.
79. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46:1853-1862.
80. Hillebrand DJ, Pfeifle J, Roberts C, Lo T, Frederick T, Gish RG. Intermittent modular plasma adsorption of cytokines and toxins (IMPACT System) in subjects with cirrhosis and hepatic encephalopathy. ASAIO Journal. 2006;52.10A.
81. Hill K, Hu KQ, Cottrell A, Teichman S, Hillebrand DJ. Charcoal-based hemodiabsorption liver support for episodic type C hepatic encephalopathy. Am J Gastroenterol 2003,98:2763-2770. (Pubitemid 38020121)
82. Malaguarnera M, Gargante MP, Malaguarnera G, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy Eur J Gastroenterol Hepatol. 2010;22:199-206.
83. Iwasa M, Nakao M, Kato Y, et al Dietary fiber decreases ammonia levels in patients with cirrhosis. Hepatology. 2005;41:217-218; author reply 219.
84. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-1449. (Pubitemid 38569067)
85. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo- controlled study. Dig Dis Sci. 2007;52:3259-3265.
86. Lighthouse J, Naito Y, Helmy A, et al. Endotoxinemia and benzodiazepine- like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation Hepatol Res. 2004;28:155-160
87. Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103:1707-1715.
88. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2008;20:506-511. (Pubitemid 351667890)
89. Nicaise C, Prozzi D, Viaene E, et al. Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. Hepatology. 2008;48:1184-1192.
90. Darkoh C, Lichtenberger LM, Ajami N, Dial EJ, Jiang ZD, DuPont HL. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 2010;54:3618-3624.
91. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
92. Sanyal A, Bass N, Mullen K, Poordad F, Shaw A. Rifaximin treatment improved quality of life in patients with hepatic encephalopathy, results of a large, randomized, placebo-controlled trial. J Hepatology. 2010;52(supp 1):S7.
93. Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010;53:849-855.
94. Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol. 2005;3:184-191. (Pubitemid 40220314)
95. Jiang Q, Jiang G, Welty TE, Zheng M. Naloxone in the management of hepatic encephalopathy. J Clin Pharm Ther. 2010;35:333-341.
96. Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;2:CD002798.
97. Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32:1080-1090.
98. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-1-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol. 2009;24:9-14.
99. Ocera. Ocera therapeutics completes first in human studies with OCR-002 for the treatment of hyperammonemia and hepatic encephalopathy. 2010
100. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev. 2003;2:CD001939.
101. Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41:38-43. (Pubitemid 39005150)
102. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci. 2008;53:3018-3025.
103. Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol. 2005;11:7197-7202. (Pubitemid 43154020)
104. Malaguarnera M, Pistone G, Astuto M, et al. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci. 2006;51:2242-2247.
105. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol. 1987;4:8-14. (Pubitemid 17045538)
106. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818-824. (Pubitemid 47374144)
107. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME trial). Am J Gastroenterol. 2011;106:307-316.